When do you consider discontinuing disease modifying therapies for multiple sclerosis?
Answer from: at Academic Institution
Certainly, age is increasingly being defined as a factor that influences disease evolution. There are some articles that suggest 55 years might be a 'turning point' to discontinue disease modifying therapies but my preference, particularly when there is no radiological or clinical worsening over the...